US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Isofol Medical AB (publ) publishes year-end report, January – December 2023

GOTHENBURG, Sweden, February 20, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January – December 2023 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Fourth quarter, October – December 2023 · Net revenue amounted to kSEK 0 (1,857) and other revenue to kSEK 0 (0) · The result for the period amounted to kSEK -8,883 (-25,284) · Earnings per share amounted to SEK -0.05 (-0.16) · Cash and bank balance on December 31 amounted to

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work since the new Board of Directors and management took office in January. The Board of Directors has decided today to prepare a new development program for arfolitixorin, with the goal of initiating new clinical studies as soon as possible. The company intends to present details of the strategic direction on March 19, along with holding an investor meeting.The information in the press release below is intended for investors.  During the past year and

Isofol appoints Magnus Hurst as new Chief Financial Officer

GOTHENBURG, Sweden, January 10, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has appointed Magnus Hurst as new Chief Financial Officer. He has broad financial experience and takes up the position with immediate effect.The information in the press release is intended for investors. Magnus Hurst has long experience in financial roles at companies such as SAS and within the Kinnevik Group. He currently holds a position as CFO and Head of Investor Relations at the biotech company Synartro and will combine this role with the new assignment as CFO

Isofol appoints Petter Segelman Lindqvist as new CEO

GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company's Board of Directors has appointed Petter Segelman Lindqvist as new Chief Executive Officer. He has extensive experience from leading roles in several international pharmaceutical companies and takes up the position with immediate effect.The information in the press release is intended for investors. Petter Segelman Lindqvist has a MSc in Business and Economics from the Stockholm School of Economics, Sweden, and EM Lyon, France. He has experiences from leading

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extraordinary general meeting (“EGM”) at which the following principal resolutions were passed.The information in the press release is intended for investors. Election of members and chairman of the board, determination of fees to the board of directors The EGM resolved that the number of members of the board of directors shall be five without deputies. The EGM resolved that the board of directors shall consist of Jan-Eric Österlund, Lars Lind, Sten Nilsson, Helena Taflin

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate’s continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of five evaluated organoids from colorectal cancer tumors. These findings are positive for Isofol and the company will implement additional bioinformatic analysis to identify potential patterns.The information in

Isofol’s board of directors announces its position on minority shareholder's proposal ahead of extraordinary general meeting

GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of minority shareholders.Following a request from a group of shareholders representing more than 10 percent of the company shares (the “Minority Shareholders”), an extraordinary general meeting will be held on January 4, 2024. The minority shareholders propose

Isofol has received the first results from laboratory tests of arfolitixorin

GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received the first results from the laboratory tests of arfolitixorin which are performed ahead of a potential decision to continue the clinical development of the drug candidate. Data generated so far from the first experiments show no difference in additional effect of arfolitixorin compared to leucovorin. Higher doses of arfolitixorin than was used in the AGENT study have been tested, but with no better effect. Further laboratory tests are ongoing and full results

Isofol is liquidating a subsidiary

GOTHENBURG, Sweden, December 1, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the subsidiary Isofol Medical (Incentive) AB, which has been dormant since 2021, will be liquidated.The information in the press release is intended for investors. The purpose of the wholly owned subsidiary Isofol Medical (Incentive) AB was to handle warrants for employees. The subsidiary has been dormant since December 2021 when the last warrants were handed over to the employees. The subsidiary's liquidation will lead to reduced costs for Isofol Medcial AB (publ). Any

Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024

GOTHENBURG, Sweden, November 21, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Extraordinary General Meeting on Thursday, January 4, 2024.N.B. This is an unofficial translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail. The information in the press release is intended for investors. Shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its

Isofol Medical AB (publ) publishes interim report, January–September 2023

GOTHENBURG, Sweden, November 10, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–September 2023 is now available, in Swedish, on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Third quarter, July – September 2023 · Net revenue amounted to TSEK 0 (2,907) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -6,260 (-32,513) · Earnings per share amounted to SEK -0.04 (-0.20) · Cash and cash equivalents as of September

Isofol has obtained a request to call an extraordinary general meeting

GOTHENBURG, Sweden, November 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an extraordinary general meeting for the election of additional board members.Information in the press release below is intended for investors. Isofol has obtained a request to call an extraordinary general meeting from shareholders representing a minority of at least 10 percent in order to take a decision on the election of additional board members. The notice to the extraordinary general meeting will be announced as soon as is practically possible. For further

Isofol appoints nomination committee ahead of the Annual General Meeting 2024

GOTHENBURG, Sweden, November 8, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2024 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2022.The information in the press release is intended for investors. According to the instructions for appointment of the nomination committee for Isofol Medical AB (publ), the nomination committee shall consist of three members,

Isofol Medical AB (publ) has taken note of the results from the Modelle 001 study

GOTHENBURG, Sweden, October 5, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), announces today that the company has taken notice of the results from the investigator-initiated study Modelle 001.The information in the press release is intended for investors. As previously informed, Sahlgrenska University Hospital in collaboration with Norrland University Hospital has conducted an investigator-initiated academic study, Modelle 001. The study included 30 patients and was led by Dr. Helena Taflin at Sahlgrenska University Hospital in Gothenburg. The aim of the study

Isofol Medical AB (publ) publishes interim report, January–June 2023

GOTHENBURG, Sweden, August 22, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–June 2023 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Second quarter, April–June 2023 · Net revenue amounted to TSEK 0 (4,027) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -7,507 (-54,033) · Earnings per share amounted to SEK -0.05 (-0.33) · Cash and cash equivalents at June 30 amounted to TSEK 156,767 (277,

Isofol presents conclusions from the in-depth analysis of the AGENT study

Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from the company's in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company's drug candidate arfolitixorin. Isofol has therefore decided to continue the development of arfolitixorin and is intensifying preparations for a possible start of a minor clinical study.The information in the press release is intended for investors. In preclinical

Isofol's Board of Directors appoints Roger Tell as acting CEO of the company

Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has decided to appoint Roger Tell as acting CEO for the company, effective immediately.The information in the press release is intended for investors. Dr. Roger Tell (b. 1965) has been active in Isofol since 2019 and is today responsible for medical and scientific issues. He first held a position as Senior Vice President of Clinical Development and Chief Scientific Officer, thereafter, moving on to a role as Chief Medical Officer. He joined Isofol from Aprea Therapeutics, where he was

CEO resigns at his own request in Isofol Medical AB (publ)

Gothenburg, Sweden, June 21, 2023 – Isofol Medical AB (publ) announces today that Thomas Andersson, at his own request, has chosen to resign as Chief Executive Officer of the company.The information in the press release is intended for investors. Isofol's CEO, Thomas Andersson, has today informed the board that he is leaving the position as Chief Executive Officer. The board will return with information about new CEO. For more information, please contact Isofol Medical AB (publ)Mats Franzén, chairman of the boardE-post: mats@efficere.se This information is information that

Changes in the board at Isofol Medical AB (publ)

Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who today has decided to resign as Board Director and instead will take a new role as senior advisor to the company.The information in the press release is intended for investors. The board has decided to co-opt Anders Edvell to the board of Isofol. Anders Edvell has over 20 years of experience in the pharmaceutical industry and is currently CEO of Immedica Pharma, a

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 3, 2023

Today on May 3, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed.The information in the press release is intended for investors. Adoption of income statements and balance sheets for 2022 and discharge from liability The AGM resolved to adopt the income statements and balance sheets for the company and the group for the financial year 2022. The members of the board of directors and the CEO were discharged from liability for the financial year 2022. Allocation of

Isofol Medical AB (publ) publishes interim report, January–March 2023

GOTHENBURG, Sweden, May 3, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–March 2023 is now available, in Swedish, on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. First quarter, January–March 2023 · Net revenue amounted to TSEK 721 (4,006) and other revenue to TSEK 23 (1) · The result for the period amounted to TSEK -14,395 (-47,874) · Earnings per share amounted to SEK -0.09 (-0.30) · Cash and cash equivalents on March 31 amounted to

Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS

Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated a preclinical research collaboration with the Norwegian biotech company Oncosyne AS, to evaluate the effect of the drug candidate arfolitixorin in different doses combined with the cancer drug 5-FU, among others. This is an important step in the company´s previously communicated strategy to re-evaluate possible future tracks for arfolitixorin and to maximize the opportunities to take the drug candidate further toward potential market approval.The

Invitation to presentation of Isofol´s report for the first quarter of 2023

GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for the first quarter of 2023 on Wednesday, May 3, 2023. On the same day, Isofol invites investors, analysts, and media to an audiocast. The company´s chairman and CEO gives an update with a subsequent question and answer session.In conjunction with the publication of the interim report for the first quarter of 2023, Isofol invites investors, analysts, and media to an audiocast on May 3, 2023 at 11:00 a.m. CEST. The presentation will be held by Isofol´s

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe